Efficacy and safety of selumetinib in adults with neurofibromatosis type 1 and symptomatic, inoperable plexiform neurofibromas (KOMET): a multicentre, international, randomised, placebo-controlled, parallel, double-blind, phase 3 study
AstraZeneca
Alice P Chen; Geraldine O'Sullivan Coyne; Pamela L Wolters; Staci Martin; Said Farschtschi; Ignacio Blanco; Zhongping Chen; Luiz Guilherme Darrigo; Marica Eoli; James R Whittle; Yoshihiro Nishida; Rosa Lamarca; Randolph de la Rosa Rodriguez; Ayo Adeyemi; Idoia Herrero; Nereida Llorente; Scott J Diede; Eva Dombi; Pierre Wolkenstein; KOMET study investigators